Last reviewed · How we verify
Phase II Study Of NX 211 (Liposomal Lurtotecan) Given As An IV Bolus Injection On Days 1 and 8 Every 3 Weeks In Patients With Metastatic Or Loco-Regional Recurrent Squamous Cell Carcinoma Of The Head and Neck With Target Lesions Within Previously Irradiated Fields Or Outside Previously Irradiated Fields
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal lurtotecan in treating patients who have metastatic or locally recurrent head and neck cancer.
Details
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 50 |
| Start date | 2001-05 |
Conditions
- Head and Neck Cancer
Interventions
- liposomal lurtotecan
Countries
Austria, Belgium, France, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom